XML 74 R50.htm IDEA: XBRL DOCUMENT v3.20.4
Quarterly Financial Data (unaudited) (Tables)
 12 Months Ended
Dec. 31, 2020
Quarterly Financial Data [Abstract]  
Schedule of Quarterly Financial Information The following table presents unaudited quarterly consolidated operating results for each of our last eight quarters. The information below has been prepared on a basis consistent with our audited consolidated financial statements (in millions, except per share amounts):
First Quarter
Second
Quarter (2)
Third
Quarter (3)
Fourth
Quarter(4)
Year Ended December 31, 2020
Net sales$1,341.0 $1,219.1 $1,213.7 $1,289.5 
Gross profit$483.2 $434.7 $428.1 $469.2 
Change in financial assets$(1.6)$(2.1)$(22.2)$122.3 
Net income (loss)$106.4 $60.6 $(154.6)$(175.0)
Earnings (loss) per share(1):
Basic$0.78 $0.44 $(1.13)$(1.29)
Diluted$0.77 $0.44 $(1.13)$(1.29)
Weighted average shares outstanding:
Basic136.2 136.4 136.5 135.4 
Diluted137.3 137.5 136.5 135.4 

(1)    The sum of individual per share amounts may not equal due to rounding.
(2)    Includes Rosemont Pharmaceuticals business pre-tax loss of $21.1 million.
(3)    Includes impairment charges of $202.4 million, change in financial assets of $22.2 million and loss on early debt extinguishment of $20.0 million.
(4)    Includes change in financial assets of $122.3 million and impairment charges of $144.4 million.
First
Quarter(2)
Second
Quarter (3)
Third
Quarter (4)
Fourth
Quarter(5)
Year Ended December 31, 2019
Net sales$1,174.5 $1,149.0 $1,191.1 $1,322.8 
Gross profit$448.8 $430.8 $412.8 $480.9 
Change in financial assets$(10.4)$(5.5)$(2.6)$(3.6)
Net income (loss)$63.9 $9.0 $92.2 $(19.0)
Earnings (loss) per share(1):
Basic$0.47 $0.07 $0.68 $(0.14)
Diluted$0.47 $0.07 $0.67 $(0.14)
Weighted average shares outstanding:
Basic135.9 136.0 136.0 136.1 
Diluted136.2 136.5 136.8 137.0 

(1)     The sum of individual per share amounts may not equal due to rounding.
(2)    Includes change in financial assets of $10.4 million.
(3)    Includes impairment charges of $27.8 million and restructuring charges and other termination benefits of $12.2 million.
(4)    Includes animal health divestiture pre-tax gain of $71.7 million, Ranitidine market withdrawal charges of $18.4 million, acquisition-related charges and contingent consideration adjustments of $18.1 million, and impairment charges of $10.9 million.
(5)    Includes impairment charges of $141.6 million.